Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SHP099 is a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 32.00 | |
5 mg | In stock | $ 71.00 | |
10 mg | In stock | $ 98.00 | |
25 mg | In stock | $ 177.00 | |
50 mg | In stock | $ 259.00 | |
100 mg | In stock | $ 475.00 | |
500 mg | In stock | $ 1,050.00 | |
1 g | In stock | $ 1,390.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 63.00 |
Description | SHP099 is a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor. |
Targets&IC50 | SHP2:70 nM. |
In vitro | The X-ray co-crystal for SHP099 with SHP2 reveals a new interaction with the basic amine and the Phe113 backbone carbonyl. SHP099 exhibits inhibition of cell proliferation (KYSE-520 model) with an IC50 of 1.4 μM. SHP099 also exhibits high solubility and high permeability with no apparent efflux in Caco-2 cells[1]. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, therefore, inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signaling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells[2]. |
In vivo | Dose-dependent exposure and modulation of the pharmacodynamic marker p-ERK was observed in xenografts following single doses of 30 and 100 mg/kg (red and blue lines, respectively). A daily oral dose of 10 or 30 mg/kg yield 19% and 61% tumor growth inhibition, respectively. Tumor stasis is achieved at 100 mg/kg[1]. |
Kinase Assay | The inhibition of SHP2 from the tested compounds (SHP099) concentrations varying from 0.003-100 μM is monitored using an assay in which 0.5 nM of SHP2 is incubated with of 0.5 μM of peptide IRS1_pY1172(dPEG8)pY1222. After 30-60 minutes incubation at the surrogate substrate, DiFMUP is added to the reaction and incubated at 25 °C for 30 minutes. The reaction is then quenched by the addition of 5 μL of a 160 μM solution of bpV(Phen). The fluorescence signal is monitored using a microplate reader using excitation and emission wavelengths of 340 nm and 450 nm, respectively[1]. |
Cell Research | Cells are plated onto 96-well plates in 100 μL medium. SHP099 with various concentrations (1.25, 2.5, 5, 10, 20 μM) are added 24 h after cell plating. At day 5, 50 μL Celltiter-Glo reagent is added, and the luminescent signal is determined[1]. |
Molecular Weight | 388.72 |
Formula | C16H20Cl3N5 |
CAS No. | 2200214-93-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Methanol: 15 mg/mL (38.59 mM), sonification is recommended.
DMSO: 55 mg/mL (141.49 mM), Sonification/heating is recommended.
H2O: 10 mg/mL (25.73 mM), Sonification is recommended
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SHP099 hydrochloride 2200214-93-1 Metabolism Others Phosphatase SHP-099 SHP099 Hydrochloride SHP 099 Inhibitor SHP 099 Hydrochloride inhibit SHP-099 Hydrochloride SHP-099 hydrochloride SHP099 inhibitor